Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

484 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: the Dutch Cangrelor registry.
Selvarajah A, Tavenier AH, Bor WL, Houben V, Rasoul S, Kaplan E, Teeuwen K, Hofma SH, Lipsic E, Amoroso G, van Leeuwen MAH, Ten Berg JM, van 't Hof AWJ, Hermanides RS. Selvarajah A, et al. Among authors: ten berg jm. Eur Heart J Open. 2021 Oct 18;1(3):oeab028. doi: 10.1093/ehjopen/oeab028. eCollection 2021 Nov. Eur Heart J Open. 2021. PMID: 35923807 Free PMC article. No abstract available.
High-dose tirofiban pretreatment reduces the need for bail-out study medication in patients with ST-segment elevation myocardial infarction: results of a subgroup analysis of the On-TIME 2 trial.
Hermanides RS, Heestermans AA, Ten Berg JM, Gosselink AT, Ottervanger JP, van Houwelingen KG, Kolkman JJ, Stella PR, Dill T, Hamm C, van 't Hof AW. Hermanides RS, et al. Among authors: ten berg jm. Heart. 2011 Jan;97(2):106-11. doi: 10.1136/hrt.2010.194951. Epub 2010 Oct 20. Heart. 2011. PMID: 20962338 Clinical Trial.
A comparison between upfront high-dose tirofiban versus provisional use in the real-world of non-selected STEMI patients undergoing primary PCI: Insights from the Zwolle acute myocardial infarction registry.
Heestermans AA, Hermanides RS, Gosselink AT, de Boer MJ, Hoorntje JC, Suryapranata H, Ottervanger JP, Dambrink JH, Kolkman E, Ten Berg JM, Zijlstra F, van 't Hof AW. Heestermans AA, et al. Among authors: ten berg jm. Neth Heart J. 2010 Dec;18(12):592-7. doi: 10.1007/s12471-010-0840-z. Neth Heart J. 2010. PMID: 21301621 Free PMC article.
Antithrombotic therapy in patients undergoing TAVI: an overview of Dutch hospitals.
Nijenhuis VJ, Stella PR, Baan J, Brueren BR, de Jaegere PP, den Heijer P, Hofma SH, Kievit P, Slagboom T, van den Heuvel AF, van der Kley F, van Garsse L, van Houwelingen KG, Van't Hof AW, Ten Berg JM. Nijenhuis VJ, et al. Among authors: ten berg jm. Neth Heart J. 2014 Feb;22(2):64-9. doi: 10.1007/s12471-013-0496-6. Neth Heart J. 2014. PMID: 24287807 Free PMC article.
The extent of ST elevation and ST deviation as predictors of mortality in ST-segment elevation myocardial patients planned to undergo primary percutaneous coronary intervention.
Postma S, Dambrink JHE, Gosselink ATM, Ottervanger JP, Kolkman E, Ten Berg JM, Suryapranata H, Van't Hof AWJ. Postma S, et al. Among authors: ten berg jm. Int J Cardiol. 2016 Feb 15;205:31-36. doi: 10.1016/j.ijcard.2015.11.177. Epub 2015 Nov 28. Int J Cardiol. 2016. PMID: 26709137
484 results